Pegylated interferon alpha2a

DRUG6 trials

Sponsors

French National Agency for Research on AIDS and Viral Hepatitis, University Hospital, Geneva, Enyo Pharma, University of Utah, Replicor Inc.

Conditions

Ascites HepaticChronic Hepatitis CCirrhosis, LiverDecompensated CirrhosisHepatitis B, ChronicHepatitis CHepatocellular CarcinomaMyelofibrosis

Phase 1

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis

RecruitingNCT05535764

University of UtahMyelofibrosis

Start: 2023-08-02End: 2027-10-30Target: 18Updated: 2025-05-07

Phase 2

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

CompletedNCT04365933

Enyo PharmaHepatitis B, Chronic

Start: 2020-05-25End: 2021-11-29Updated: 2022-08-25

Phase 3

Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)

CompletedNCT00158496

French National Agency for Research on AIDS and Viral HepatitisChronic Hepatitis C

Start: 2002-08-31End: 2005-01-31Target: 100Updated: 2007-04-24

Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)

CompletedNCT00158522

French National Agency for Research on AIDS and Viral HepatitisHepatitis C

Start: 2003-02-28End: 2007-12-31Updated: 2008-02-08

Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant

CompletedNCT00466219

University Hospital, GenevaHepatitis C

Start: 2002-05-31End: 2006-12-31Target: 25Updated: 2007-04-27

Unknown Phase

Replicor Compassionate Access Program

Replicor Inc.Ascites Hepatic, Cirrhosis, Liver, Decompensated Cirrhosis +4

Updated: 2025-02-17

Related Papers

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

2025-11-061 citations